Matrix metalloproteinase-9 inhibition or deletion attenuates portal hypertension in rodents

Keyphrases

• Matrix metalloproteinase-9 (MMP-9) 100%
• Rodents 100%
• Portal Hypertension 100%
• Matrix Metalloproteinases 50%
• Liver Cirrhosis 50%
• Liver Fibrosis 50%
• Angiogenesis 33%
• Shunt 33%
• Protein Expression 33%
• Matrix Metalloproteinase Inhibitors 33%
• Cirrhosis 33%
• Derangement 33%
• Minocycline 33%
• Bile Duct Ligation 33%
• Vascular Density 33%
• Phosphorylation 16%
• Liver 16%
• Endothelial Nitric Oxide Synthase (eNOS) 16%
• Non-selective 16%
• VEGF Levels 16%
• Sham 16%
• Sprague-Dawley Rats 16%
• Matrix metalloproteinase-2/9 16%
• Knock 16%
• Smad2 16%
• Fibrosis Liver 16%
• Hyperdynamic Circulation 16%
• Common Bile Duct Ligation 16%
• Portosystemic Collaterals 16%
• Fibrogenesis 16%
• Hemodynamic Abnormalities 16%
• Plasma VEGF 16%

Medicine and Dentistry

• Gelatinase B 100%
• Portal Hypertension 100%
• Liver Cirrhosis 83%
• Matrix Metalloproteinase 66%
• Liver Fibrosis 50%
• Bile Duct Ligation 50%
• Angiogenesis 33%
• Hemodynamic 33%
• Protein Expression 33%
• Vasculotropin 33%
• Shunting 33%
• Minocycline 33%
• Gelatinase A 16%
• Knock Out 16%
• Common Bile Duct 16%
• Fibrogenesis 16%
• Matrix Metalloproteinase Inhibitor 16%